February 25, 2009
Teikoku Enters into an Agreement with Eisai for the Development of a Transdermal Patch Formulation of Donepezil Hydrochloride
Teikoku Seiyaku Co., Ltd. (Headquarters: Kagawa, President and CEO: Shosaku Murayama, “Teikoku Seiyaku”) and its U.S. subsidiary, Teikoku Pharma USA, Inc. (Headquarters: California, President and CEO: Masahisa Kitagawa, “Teikoku USA”) have entered into the following agreements with Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) on development of transdermal patch formulation.
1. License Agreement (except Japan)
Teikoku Pharma USA and Eisai have entered into a license agreement on the donepezil patch currently being developed in all territories except Japan. This agreement grants Eisai the exclusive marketing rights for the donepezil patch in all territories except Japan as well as the exclusive development rights of the donepezil patch in all territories except the U.S. and Japan. This agreement also grants Eisai option rights to enter into an exclusive license agreement for development and commercialization of the next generation product of the donepezil patch in all territories except Japan.
2. Option Agreement (Japan)
Teikoku Seiyaku and Eisai entered into an option agreement on the donepezil patch in Japan. This agreement grants Eisai option rights to enter into an exclusive license agreement for research, development and commercialization in Japan.
With this agreement, we will introduce a new alternative to the donepezil hydrochloride tablet to treat Alzheimer’s disease currently marketed by Eisai (the product name in Japan: “Aricept®”). Teikoku Seiyaku currently directs its focus on anti-inflammatory products such as the patch and the tape and the two main goals in its R&D are “pain relief” and “application of transdermal absorption technology”. We will strive to strengthen our product line utilizing transdermal absorption technology and to improve the quality of life for patients.
Contact: Teikoku Pharma USA, Inc.